News Virax Biolabs Group Limited

Stocks

VRAX

KYG9495L1251

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 11/06/2026 BST			5-day change	1st Jan Change
0.1824 ^USD	+3.05%		-7.93%	-47.25%

05-26	Virax Biolabs Group Limited Reports Positive Early Clinical Data for Viraximmune in Long Covid and Related Post-Acute Infection Syndromes	CI
03-18	Virax Biolabs Group Limited Approves Fourth Amended and Restated Memorandum and Articles of Association	CI

All News

Mentions Relevance

05-26	Virax Biolabs Group Limited Reports Positive Early Clinical Data for Viraximmune in Long Covid and Related Post-Acute Infection Syndromes	CI
04-14	Virax Biolabs : Investor Presentation (Virax Biolabs Investor Deck Q2 2026)	PU
03-31	Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation	PR
03-18	Virax Biolabs Group Limited Approves Fourth Amended and Restated Memorandum and Articles of Association	CI
12-04	Virax Biolabs : Announces Closing of $5 Million Private Placement	PU
12-04	Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement	PR
12-03	Virax Biolabs Group Limited announced that it has received $4.99875 million in funding	CI
12-03	Virax Biolabs : Announces $5 Million Private Placement	PU
12-03	Virax Biolabs Group Limited Announces $5 Million Private Placement	PR
12-03	Virax Biolabs' : CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders	PU
12-03	Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders	PR
12-02	Virax Biolabs Group Limited announced that it expects to receive $4.99875 million in funding	CI
12-02	Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2025	CI
11-03	Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes	PR
11-03	Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive Fda Feedback for Viraximmune?? Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes	CI
27/10/25	Virax Biolabs : Investor Presentation (Virax Biolabs Investor Deck October 2025 FINAL V2)	PU
10/10/25	Virax Biolabs : Investor Presentation (Virax Biolabs Investor Deck October 2025)	PU
26/08/25	Virax Biolabs to Collaborate With Emory University on Long COVID Clinical Studies	MT
26/08/25	Virax Biolabs : Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early SeptemberV	PU
26/08/25	Virax Biolabs partners with Emory University on ViraxImmune(TM) clinical studies	RE
26/08/25	Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September	PR
26/08/25	Virax Biolabs Group Limited Partners with Emory University on ViraxImmune Clinical Studies	CI
08/08/25	Virax Biolabs : Major New Study Reveals Immunological Insights Into ME/CFS, Further Supporting Blood-based Diagnostic Testing and Research	PU
29/07/25	Virax Biolabs Group Limited Announces Board Changes	CI
29/07/25	Virax Biolabs Group appoints Iain Miller, Ph.D. as independent director to accelerate commercial strategy	RE